» Articles » PMID: 37438361

The Pharmacological Bases for Repurposing Statins in Depression: a Review of Mechanistic Studies

Overview
Date 2023 Jul 12
PMID 37438361
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are commonly prescribed medications widely investigated for their potential actions on the brain and mental health. Pre-clinical and clinical evidence suggests that statins may play a role in the treatment of depressive disorders, but only the latter has been systematically assessed. Thus, the physiopathological mechanisms underlying statins' putative antidepressant or depressogenic effects have not been established. This review aims to gather available evidence from mechanistic studies to strengthen the pharmacological basis for repurposing statins in depression. We used a broad, well-validated search strategy over three major databases (Pubmed/MEDLINE, Embase, PsychINFO) to retrieve any mechanistic study investigating statins' effects on depression. The systematic search yielded 8068 records, which were narrowed down to 77 relevant papers. The selected studies (some dealing with more than one bodily system) described several neuropsychopharmacological (44 studies), endocrine-metabolic (17 studies), cardiovascular (6 studies) and immunological (15 studies) mechanisms potentially contributing to the effects of statins on mood. Numerous articles highlighted the beneficial effect of statins on depression, particularly through positive actions on serotonergic neurotransmission, neurogenesis and neuroplasticity, hypothalamic-pituitary axis regulation and modulation of inflammation. The role of other mechanisms, especially the association between statins, lipid metabolism and worsening of depressive symptoms, appears more controversial. Overall, most mechanistic evidence supports an antidepressant activity for statins, likely mediated by a variety of intertwined processes involving several bodily systems. Further research in this area can benefit from measuring relevant biomarkers to inform the selection of patients most likely to respond to statins' antidepressant effects while also improving our understanding of the physiopathological basis of depression.

Citing Articles

Improving topic modeling performance on social media through semantic relationships within biomedical terminology.

Xin Y, Grabowska M, Gangireddy S, Krantz M, Kerchberger V, Dickson A PLoS One. 2025; 20(2):e0318702.

PMID: 39982945 PMC: 11845042. DOI: 10.1371/journal.pone.0318702.


Prospective and challenges of locally applied repurposed pharmaceuticals for periodontal tissue regeneration.

El-Nablaway M, Rashed F, Taher E, Abdeen A, Taymour N, Soliman M Front Bioeng Biotechnol. 2024; 12:1400472.

PMID: 39605747 PMC: 11600316. DOI: 10.3389/fbioe.2024.1400472.


Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.

Aldossary K, Ali L, Abdallah M, Bahaa M, Elmasry T, Elberri E Front Pharmacol. 2024; 15:1381523.

PMID: 38855751 PMC: 11157054. DOI: 10.3389/fphar.2024.1381523.


Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study.

De Giorgi R, De Crescenzo F, Ostinelli E, Cowen P, Harmer C, Fazel S BMJ Ment Health. 2024; 27(1).

PMID: 38772637 PMC: 11110566. DOI: 10.1136/bmjment-2024-301035.


Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study.

De Giorgi R, De Crescenzo F, Cowen P, Harmer C, Cipriani A BMC Med. 2023; 21(1):424.

PMID: 37936200 PMC: 10631198. DOI: 10.1186/s12916-023-03138-5.

References
1.
Salo K, Scharfen J, Wilden I, Schubotz R, Holling H . Confining the Concept of Vascular Depression to Late-Onset Depression: A Meta-Analysis of MRI-Defined Hyperintensity Burden in Major Depressive Disorder and Bipolar Disorder. Front Psychol. 2019; 10:1241. PMC: 6555192. DOI: 10.3389/fpsyg.2019.01241. View

2.
Wirleitner B, RUDZITE V, Neurauter G, Murr C, Kalnins U, Erglis A . Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 2003; 33(7):550-4. DOI: 10.1046/j.1365-2362.2003.01186.x. View

3.
Fava M . The promise and challenges of drug repurposing in psychiatry. World Psychiatry. 2018; 17(1):28-29. PMC: 5775121. DOI: 10.1002/wps.20481. View

4.
Yatham M, Yatham K, Ravindran A, Sullivan F . Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. J Affect Disord. 2019; 257:55-63. DOI: 10.1016/j.jad.2019.07.002. View

5.
Renshaw P, Parsegian A, Yang C, Novero A, Yoon S, Lyoo I . Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats. Pharmacol Biochem Behav. 2008; 92(1):88-92. PMC: 2666925. DOI: 10.1016/j.pbb.2008.10.017. View